May 5th 2024
Are individuals with bipolar disorder more likely to die from unnatural causes than the general population?
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Advances In™ Schizophrenia: Expanding the Therapeutic Landscape
View More
Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia
View More
Southern California Psychiatry Conference
September 13-14, 2024
Register Now!
Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder
View More
5th Annual International Congress on the Future of Neurology®
View More
2023 Annual Psychiatric Times™ World CME Conference
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Real Psychiatry 2025
January 2025 - Exact Date TBA
View More
More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Update on the Treatment of Bipolar Depression
November 6th 2012There are many rapidly effective treatments for mania in bipolar disorder. However, there are relatively few options for bipolar depression, and none that are rapidly effective-even though bipolar depression constitutes between 20% to 50% of all depressive disorders.
Listen
Are Psychiatric Disorders Inflammatory-Based Conditions?
A plethora of studies support the hypothesis that inflammation plays a role in the pathophysiology of major psychiatric disorders.
Read More
Irreversible Monoamine Oxidase Inhibitors Revisited
October 8th 2012Given the likelihood that insufficient numbers of patients will be available for a randomized controlled trial of MAOIs in refractory depression or atypical depression, we must still rely on consensus guidelines and expert opinion.
Read More
Psychiatric Disorders Associated With Suicide
September 12th 2012Suicide involves a complex array of psychological, biological, social, and cultural factors, and it is particularly likely to occur during periods of individual, family, and socioeconomic crises associated with loss and shame. What 3 psychiatric disorders are most often associated with suicide?
Read More
Coming Along With the DSM-5: Hybrid Models of Psychiatric Diagnosis
September 12th 2012Do not be surprised if you hear more about hybrid models of psychiatric diagnoses included in DSM-5. The categorical and dimensional model approaches are 2 sides of the same coin as you look at the same patient from 2 different angles.
Read More
Effective Personalized Strategies for Treating Bipolar Disorder
August 2nd 2012Effective personalized treatment recognizes bipolar disorder as a biopsychosocial disorder, but mood-stabilizing medications are the backbone of treatment. These medications fall into 3 categories: lithium, antikindling/antiepileptic agents, and second-generation antipsychotics.
Read More
Personalized Biological Testing in Psychiatry: Inevitable Reality or Impossible Dream?
July 19th 2012Our current diagnostic system is based more on subjective clinical judgments and less biological psychiatry. There is not one way to develop symptoms of schizophrenia or bipolar disorder or autistim or OCD.
Read More
Confounding Factors in TRD (Part 1): The Role of Subtyping and Bipolarity
July 19th 2012The current system of payment for mental health care in the US can lead, or even incentivize, clinicians to focus on and code for Axis I disorders and their more readily reimbursed psychopharmacological treatment approaches.
Read More
Ketamine-Induced Optimism: New Hope for the Development of Rapid-Acting Antidepressants
July 14th 2012There is rapidly escalating interest in drugs that target the glutamatergic neurotransmitter system, especially NMDA receptor modulators. The hope is that they will fill the large unmet need for rapid-acting antidepressant medications with efficacy in treatment-resistant depression.
Read More
The Duty to Protect: When Has It Been Discharged?
July 2nd 2012The California Supreme Court’s decision in the Tarasoff case over 30 years ago has become a standard part of mental health practice. This case influenced the legal requirements governing therapists’ duty to protect third parties in nearly every state in the US.
Read More
How to End a Psychiatric Epidemic: The Redemption of Psychiatry
June 12th 2012In light of our problems and uncertainties about the state of current psychiatry, or perhaps because of them, what might describe good psychiatry? Following are some suggestions for what we, as psychiatrists, can do.
Read More
Does Evidence-Based Medicine Discourage Richer Assessment of Psychopathology and Treatment?
April 5th 2012The paradigm for modern psychiatry is evidence-based medicine (EBM)-it represents proven treatments for defined diagnoses. But there are major problems with this position, starting with the fact that while they are superior to placebo, evidence-based treatments too often are ineffective.
Read More
Introduction: Strategies for Treatment
April 3rd 2012When thinking about recent advances in psychopharmacology, we often point to new molecules with similar mechanisms of action but with better safety and tolerability profiles, or to molecules with novel mechanisms that effect positive change greater than that with existing treatments.
Read More